Overview of demographics for subjects enrolled in the study
| Study ID No. . | Sex . | Race . | Age at screen, y . | Duration of HIV infection, y† . | CD4 nadir . | Baseline CD4 abs . | Date of first infusion . | No. of infusions . | No. of gene-modified cells at ATI, per million PBMCs . | ATI date . | Restarted meds . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 201* | Female | White | 40 | 2 | 513 | 852 | 10/11/06 | 6 | 2000 | 02/22/07 | 02/15/10, ∼ 12 mo after ATI |
| 202* | Male | Black | 37 | 10 | 197 | 355 | 1/9/07 | 6 | 1000 | 05/16/07 | 07/26/07, ∼ 2 mo after ATI |
| 203* | Male | White | 55 | 14.5 | 134 | 539 | 2/13/07 | 6 | 500 | 06/19/07 | 12/11/08, ∼ 18 mo after ATI |
| 204* | Male | White | 31 | 9 | 104 | 451 | 5/22/07 | 6 | 300 | 09/27/07 | 07/8/08, ∼ 9 mo after ATI |
| 206* | Male | White | 44 | 4 | 170 | 605 | 5/29/07 | 6 | 900 | 10/04/07 | 11/2/07, ∼ 1 mo after ATI |
| 207 | Male | White | 55 | 7 | 76‡ | 578 | 7/16/07 | 6 | 200 | 11/19/07 | 12/7/07, ∼ 18 d after ATI |
| 208 | Male | White | 42 | 18 | 185‡ | 497 | 7/26/07 | 6 | 100 | No ATI | NA |
| 209 | Male | White | 49 | 9 | 78‡ | 543 | 10/23/07 | 6 | 100 | No ATI | NA |
| 211 | Male | White | 62 | 4.5 | 153‡ | 344 | 10/16/07 | 6 | 0 | No ATI | NA |
| 212 | Male | Black | 35 | 13 | 190‡ | 503 | 11/13/07 | 6 | 1200 | 03/20/08 | 07/9/08, ∼ 3 mo after ATI |
| 213 | Male | White | 43 | 19 | 50‡ | 372 | 1/30/08 | 6 | N/A | No ATI | NA |
| 214* | Male | Black and white | 43 | 23 | 160 | 443 | 4/23/08 | 3 | 200 | 09/04/08 | 10/21/08, ∼ 5 wk after ATI |
| 215* | Male | White | 41 | 6 | 247 | 680 | 08/20/08 | 6 | 100 | 01/29/09 | Pending§ |
| 218* | Female | Black | 38 | 12 | 319 | 948 | 02/25/09 | 3 | 100 | 5/5/09 | 02/08/10; ∼ 9 mo after ATI |
| 250* | Male | Other; Hispanic | 46 | 9 | 330 | 470 | 01/13/09 | 3 | 1600 | 3/31/09 | 7/20/09, ∼ 4 mo after ATI |
| 251* | Female | Black | 42 | 7 | 509 | 710 | 01/22/09 | 3 | 5400 | 4/2/09 | 8/21/09, ∼ 4 mo after ATI |
| 252* | Female | Black | 52 | 5 | 302 | 834 | 03/11/09 | 3 | 8200 | 5/27/09 | 01/14/10; ∼ 8 mo after ATI |
| Study ID No. . | Sex . | Race . | Age at screen, y . | Duration of HIV infection, y† . | CD4 nadir . | Baseline CD4 abs . | Date of first infusion . | No. of infusions . | No. of gene-modified cells at ATI, per million PBMCs . | ATI date . | Restarted meds . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 201* | Female | White | 40 | 2 | 513 | 852 | 10/11/06 | 6 | 2000 | 02/22/07 | 02/15/10, ∼ 12 mo after ATI |
| 202* | Male | Black | 37 | 10 | 197 | 355 | 1/9/07 | 6 | 1000 | 05/16/07 | 07/26/07, ∼ 2 mo after ATI |
| 203* | Male | White | 55 | 14.5 | 134 | 539 | 2/13/07 | 6 | 500 | 06/19/07 | 12/11/08, ∼ 18 mo after ATI |
| 204* | Male | White | 31 | 9 | 104 | 451 | 5/22/07 | 6 | 300 | 09/27/07 | 07/8/08, ∼ 9 mo after ATI |
| 206* | Male | White | 44 | 4 | 170 | 605 | 5/29/07 | 6 | 900 | 10/04/07 | 11/2/07, ∼ 1 mo after ATI |
| 207 | Male | White | 55 | 7 | 76‡ | 578 | 7/16/07 | 6 | 200 | 11/19/07 | 12/7/07, ∼ 18 d after ATI |
| 208 | Male | White | 42 | 18 | 185‡ | 497 | 7/26/07 | 6 | 100 | No ATI | NA |
| 209 | Male | White | 49 | 9 | 78‡ | 543 | 10/23/07 | 6 | 100 | No ATI | NA |
| 211 | Male | White | 62 | 4.5 | 153‡ | 344 | 10/16/07 | 6 | 0 | No ATI | NA |
| 212 | Male | Black | 35 | 13 | 190‡ | 503 | 11/13/07 | 6 | 1200 | 03/20/08 | 07/9/08, ∼ 3 mo after ATI |
| 213 | Male | White | 43 | 19 | 50‡ | 372 | 1/30/08 | 6 | N/A | No ATI | NA |
| 214* | Male | Black and white | 43 | 23 | 160 | 443 | 4/23/08 | 3 | 200 | 09/04/08 | 10/21/08, ∼ 5 wk after ATI |
| 215* | Male | White | 41 | 6 | 247 | 680 | 08/20/08 | 6 | 100 | 01/29/09 | Pending§ |
| 218* | Female | Black | 38 | 12 | 319 | 948 | 02/25/09 | 3 | 100 | 5/5/09 | 02/08/10; ∼ 9 mo after ATI |
| 250* | Male | Other; Hispanic | 46 | 9 | 330 | 470 | 01/13/09 | 3 | 1600 | 3/31/09 | 7/20/09, ∼ 4 mo after ATI |
| 251* | Female | Black | 42 | 7 | 509 | 710 | 01/22/09 | 3 | 5400 | 4/2/09 | 8/21/09, ∼ 4 mo after ATI |
| 252* | Female | Black | 52 | 5 | 302 | 834 | 03/11/09 | 3 | 8200 | 5/27/09 | 01/14/10; ∼ 8 mo after ATI |
Historic viral load set point was available (patients 202, 206, and 214 stopped ATI too soon to establish a post-ATI set point).
At screening.
Value was self-reported by the subject. A laboratory report was not provided to verify the information.
Remains off ART at the time of submission of this manuscript (November 2012).